Pharmaceutical formulations comprising at least one of the kinase inhibitor compounds of formula (1) together with a pharmaceutically acceptable carrier, diluent or excipient. Claim 1: A compound of formula (1) and its derivatives, prodrugs, N-oxides, stereoisomers, solvates, pharmaceutically acceptable salts and biologically active metabolites thereof； characterized in that, X is selected from O, S, and NH； A is selected from aryl or heteroaryl； R at each occurrence is independently selected from hydrogen, cyano, halo, hydroxy, -NO₂,-R83088；1. Selective replacement, selective replacement, selective replacement or cyclo armour replacement, selective replacement or non cyclo armour replacement or selective replacement； in each case, halide, asphalt, halogen, cyanogen - No. 8310 o-coor8311811 alternative is not considered；Each time R1 appears, hydrogen, halogen, tar, arilo, isocyclic propene, isocyclic propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl propenyl a. Halide, cyanide or halide； and selected as direct link, O -, C (o) - or nr8311；In each case, R2 was screened without considering hydrogen, anthrax, cyanogen, hydrogen Xi, hydrogen peroxide, tar, arilo, hetero-so83222； r83090 or oxo； R3 and r830808, but without considering hydrogen, hydrogen peroxide, amino group, optional alternative tar, optional isocycloethane, a. In each case, the alternative is chosen, regardless of halide, halide or cour8311；R83099 and r8310e should be independent of hydrogen, hydrocarbon, cor8311o-coor8311；Each substance in r83111111 is selected independently from hydrogen or hydrocarbon； m, N, and P are selected from 1, 2, or 3.Formulaciones farmacéuticas que comprenden al menos uno de los compuestos inhibidores de quinasa de fórmula (1) junto con un vehículo, diluyente o excipiente aceptable des
